@article{ee75442c38a145bf92150ddc40043876,
title = "Ocular gene therapy for neovascular AMD: a new era? {\textendash} Authors' reply",
author = "Campochiaro, \{Peter A.\} and Heier, \{Jeffrey S.\} and Saleema Kherani and Annaig Le-Halpere and Abraham Scaria",
note = "Funding Information: PAC reports grants and personal fees from Alimera, Allergan, AsclipiX, Rxi, Regenexbio, Aerpio, Genentech/Roche; grants from Abbvie, GlaxoSmithKline, Oxford BioMedica, Regeneron; and personal fees from Applied Genetic Technologies, Allegro, Intrexon, Merck, Novartis, and Bayer, outside of the submitted work. JSH and PAC report grants from Genzyme during the conduct of the study. JSH reports grants and personal fees from Acucela, Daiichi, Eyegate Pharmaceuticals, Genentech/Roche, Janssen R\&D, Ocudyne, Regeneron, SciFluor Life Sciences; personal fees from Adverum, Aerie, Aerpio Therapeutics, Alcon, Allegro Ophthalmics, Allergan, Kala Pharmaceuticals, Kanghong, Notal Vision, Regenxbio, RetroSense, Stealth Biotherapeutics, Valeant Pharmaceuticals, Voyager Therapeutics; grants from Apellis, Astellas, Bayer, Corcept, Genzyme, LPath, Neurotech, Novartis, Ophthotech, Thrombogenics, Tyrogenex; and other from Ocular Therapeutics, outside of the submitted work. AL-H and AS are current employees of Sanofi Genzyme. AS has two patents issued (US 7928072, US 8658602). SK declares no competing interests.",
year = "2017",
month = nov,
day = "11",
doi = "10.1016/S0140-6736(17)32424-8",
language = "English (US)",
volume = "390",
pages = "2140",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier B.V.",
number = "10108",
}